Dette var svaret som kom når jeg spurte hva Nieba la i begrepet right deal, foruten å bare henvise til «creating shareholder value».
Egberts var den som svarte:
Shareholder value is probably one of the key drivers. So to actually – yes, I’m not sure I’m answering the question. I mean we have not finalized our go-to-market strategy. We’re really focusing on the technical study at the moment, but it doesn’t mean we haven’t thought about it.
I think the emergent thinking is that we probably need different types of partnership in different parts of the world.
And let me just talk about the 2 extremes. Like Nordic countries, that’s probably an area we could easily do ourselves.
If you talk about places like China and the Far East, we almost certainly cannot do it on our own.
And there in between, there are a lot of other countries where different strategies might be pursued. That hasn’t been finalized yet. And so that’s where we are.
There are ongoing discussions, but that’s the best I can say at this moment. -
I tillegg la Marco til følgende:
We cannot deny that we are in dialogue with all players who are present in the hematology space, players who appreciate the value the radiopharmaceuticals can bring to the treatment of cancer. But all of these dialogues have 1 goal in mind, which is to put Betalutin of Nordic Nanovector on their radar screen and explore at the appropriate point in time the best option as highlighted. I don’t think I would add more than that. -----------
